So let me get this straight. The group that includes the fired CO who held up clinical trials for more than half a year, says that the current do-nothing management has not done much, just gotten a whole bunch of clinical trials in operation for multiple applications of the drug.

And that because the do-nothing board has done all this stuff, the 13D group will come in and quickly get approval for the drug -- on the basis of what the do-nothing management has accomplished after getting rid of the 13D former CEO.

Does that sum it up?